Cost Effectiveness Analysis of Boceprevir (BOC) Added to Pegifn/Ribavirin (P/R) Versus Pegifn/Ribavirin (Current Standard of Care) for the Treatment of Patients with Genotype 1 Chronic Hepatitis C in Greece
Abstract
Authors
K. Athanasakis E. Karampli M.P. Retsa T. Theodoropoulou J. Kyriopoulos